Another J&J recall as Animas pulls insulin cartridges; Merck: Selling Dutch ops too expensive;

@FiercePharma:  FDA may disappoint pharma on social media. Report | Follow @FiercePharma

> Johnson & Johnson's Animas unit recalled leaking insulin cartridges, saying they may cause pumps to deliver too little medicine to patients, in the latest of a growing list of J&J recalls. Article

> The debate around the closure of Merck's R&D and manufacturing unit in Oss, the Netherlands, rumbles on, with the drugmaker forced to explain its decision not to sell the plant in a Dutch court. Report

> Doctors are being contacted to organize a clinical trial for a copy of Teva Pharmaceutical Industries' multiple sclerosis medicine Copaxone, a Teva executive said. Story

> Genzyme said its board is urging shareholders to accept Sanofi-Aventis' offer to buy all outstanding shares of the company's common stock for $74 and one contingent value right per share. Report

> Actelion's management--and its philosophy of remaining independent--has received a boost from a major Swiss investor. News

> A Kent MP has urged the UK government to push Pfizer to defer redundancies at its Sandwich, England, plant to lessen the impact of the site closure. Article

> India's 'lopsided' duty structure is hurting domestic manufacturers of active pharmaceutical ingredients and feeding businesses in China, according to some Indian firms. Story

> Members of Congress, including Democrats, have urged the Obama administration to search for another Medicare chief after concluding that the Senate is unlikely to confirm President Obama's temporary appointee, Donald Berwick. Item

> The U.K.'s National Health Service chiefs are more concerned with tightening purse strings than actually putting in place the government's health reforms, suggest findings of a survey by the NHS Confederation. Report

> "Confusing" instructions on medicine bottles and packs dispensed by UK pharmacies are to be replaced with simpler words and phrases, starting from this month. News

Biotech News

@FierceBiotech: Genzyme's Termeer to pocket up to $221M. News | Follow @FierceBiotech

 @JohnCFierce: Additional point: $55 million is what you'd often see a promising biotech raise in VC funds ahead of Phase II. Follow @JohnCFierce

> Amicus to relaunch a Ph2 Pompe drug study after FDA lifts hold. News

> Biotech clusters defend their turf as challenges mount. Article

> Repligen shares tank after depression drug flunks a Ph2b. Report

> Confidence grows in mega-blockbuster approval for HGS's Benlysta. Story

Biotech Research News

> Scientists alarmed at mutations in adult stem cells. Item

> New microscope gives researchers 3D 'omniscience'. Article

> Scientists sink claws into toenails as cancer marker. Story 

> Scientists find more heart-attack genes. News

> Stem cells could replace neurons lost to Alzheimer's. Article

> Noninvasive Down syndrome test developed. Report

Pharma Manufacturing News

> Congress abets drugmaker rebate secrecy. News

> Congress enlists GAO in drug shortages probe. Item

> Fujifilm, Samsung ops notion misguided. Report

> Another drug security threat: pharmacists. News 

> Merck feels pain of Schering ops integration. Article 

> Experts prep drug operations for move to farm. Story

And Finally... Johnson & Johnson is among more than a dozen previously unidentified companies whose networks were broken into in the past two years by hackers intent on stealing some of their most valuable assets, confidential e-mails show. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.